Spectrum Pharmaceuticals Announces Authorization Of Stock Repurchase Program up to $100 Million
07:00 EDT 10 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that the
Company’s Board of D...
Other Sources for this Article
Spectrum Pharmaceuticals
Shiv Kapoor, 702-835-6300
Vice
President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com
More From BioPortfolio on "Spectrum Pharmaceuticals Announces Authorization Of Stock Repurchase Program up to $100 Million"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
